BOCA RATON, Fla.–(BUSINESS WIRE)–SurGenTec® has received additional FDA 510(k) clearance for OsteoFlo® HydroFiber™, its advanced synthetic bone graft, marking another key regulatory milestone. This expansion of indications now includes use as a bone void filler for the treatment of tumors, cysts, trauma, and osteomyelitis. This landmark clearance represents a significant advancement in the capabilities of SurGenTec®’s cutting-edge technology and highlights the company’s commitment to enhancing patient care in orthopedic and spine surgery.